ESSA PHARMA INC (EPIX)
CA29668H7085 - Common Stock
ESSA PHARMA INC
NASDAQ:EPIX (11/21/2024, 10:13:28 AM)
1.8
+0.07 (+4.05%)
Company Profile
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 50 full-time employees. The company went IPO on 2021-02-22. The firm is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The firm is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The firm is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
Company Info
ESSA PHARMA INC
999 West Broadway, Suite 720
Vancouver BRITISH COLUMBIA V5Z 1K5
P: 17783310962
CEO: David Parkinson
Employees: 50
Website: https://www.essapharma.com/
EPIX News
3 days ago - Pomerantz LLPSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX). Such investors are...
16 days ago - ChartmillWhich stocks have an unusual volume on Tuesday?Let's explore the current happenings on the US markets on Tuesday. Below, you'll find the stocks exhibiting unusual volume in today's session.
17 days ago - ChartmillIn today's session, these stocks are experiencing unusual volume.Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
20 days ago - ChartmillThese stocks are moving in today's after hours sessionLet's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
21 days ago - ESSA Pharma IncESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerEfficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to...
2 months ago - ESSA Pharma IncESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO CongressCombination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion...
EPIX Twits
Here you can normally see the latest stock twits on EPIX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
